{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T11:18:02Z","timestamp":1784546282024,"version":"3.55.0"},"reference-count":46,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2022,6,27]],"date-time":"2022-06-27T00:00:00Z","timestamp":1656288000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["#HRC-154126"],"award-info":[{"award-number":["#HRC-154126"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,7,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>There are no randomized control trials (RCTs) comparing gemcitabine and nab-paclitaxel (Gem-Nab) and fluorouracil, folinic acid, irinotecan, oxaliplatin (FOLFIRINOX) for advanced pancreatic cancer (APC). Although it is well known that RCT-based efficacy often does not translate to real-world effectiveness, there is limited literature investigating comparative cost-effectiveness of Gem-Nab vs FOLFIRINOX for APC. We aimed to examine the real-world cost-effectiveness of Gem-Nab vs FOLFIRINOX for APC in Ontario, Canada.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>This study compared patients treated with first-line Gem-Nab or FOLFIRINOX for APC in Ontario from April 2015 to March 2019. Patients were linked to administrative databases. Using propensity scores and a stabilizing weights method, an inverse probability of treatment weighted cohort was developed. Mean survival and total costs were calculated over a 5-year time horizon, adjusted for censoring, and discounted at 1.5%. Incremental cost-effectiveness ratio and net monetary benefit were computed to estimate cost-effectiveness from the public health-care payer\u2019s perspective. Sensitivity analysis was conducted using the propensity score matching method.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>A total of 1988 patients were identified (Gem-Nab: n\u2009=\u2009928; FOLFIRINOX: n\u2009=\u20091060). Mean survival was lower for patients in the Gem-Nab than the FOLFIRINOX group (0.98 vs 1.26 life-years; incremental effectiveness = \u22120.28 life-years [95% confidence interval = \u22120.47 to \u22120.13]). Patients in the Gem-Nab group incurred greater mean 5-year total costs (Gem-Nab: $103\u200a884; FOLFIRINOX: $101\u200a518). Key cost contributors include ambulatory cancer care, acute inpatient hospitalization, and systemic therapy drug acquisition. Gem-Nab was dominated by FOLFIRINOX, as it was less effective and more costly. Results from the sensitivity analysis were similar.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Gem-Nab is likely more costly and less effective than FOLFIRINOX and therefore not considered cost-effective at commonly accepted willingness-to-pay thresholds.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/jncics\/pkac047","type":"journal-article","created":{"date-parts":[[2022,6,27]],"date-time":"2022-06-27T12:41:32Z","timestamp":1656333692000},"source":"Crossref","is-referenced-by-count":12,"title":["Real-World Cost-Effectiveness of First-Line Gemcitabine Plus Nab-Paclitaxel vs FOLFIRINOX in Patients With Advanced Pancreatic Cancer"],"prefix":"10.1093","volume":"6","author":[{"given":"Vanessa","family":"Arciero","sequence":"first","affiliation":[{"name":"Department of Medicine, Division of Medical Oncology, Sunnybrook Health Sciences Centre, University of Toronto , Toronto, ON, Canada"},{"name":"Temerty Faculty of Medicine, University of Toronto , Toronto, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin","family":"Luo","sequence":"additional","affiliation":[{"name":"ICES , Toronto, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ambica","family":"Parmar","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Medical Oncology, Sunnybrook Health Sciences Centre, University of Toronto , Toronto, ON, Canada"},{"name":"Temerty Faculty of Medicine, University of Toronto , Toronto, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei Fang","family":"Dai","sequence":"additional","affiliation":[{"name":"Temerty Faculty of Medicine, University of Toronto , Toronto, ON, Canada"},{"name":"Canadian Centre for Applied Research in Cancer Control , Toronto, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaclyn M","family":"Beca","sequence":"additional","affiliation":[{"name":"Canadian Centre for Applied Research in Cancer Control , Toronto, ON, Canada"},{"name":"Ontario Health, Cancer Care Ontario , Toronto, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J","family":"Raphael","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Medical Oncology, Sunnybrook Health Sciences Centre, University of Toronto , Toronto, ON, Canada"},{"name":"Temerty Faculty of Medicine, University of Toronto , Toronto, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wanrudee","family":"Isaranuwatchai","sequence":"additional","affiliation":[{"name":"Canadian Centre for Applied Research in Cancer Control , Toronto, ON, Canada"},{"name":"St. Michael\u2019s Hospital, University of Toronto , Toronto, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9650-9105","authenticated-orcid":false,"given":"Steven","family":"Habbous","sequence":"additional","affiliation":[{"name":"Ontario Health, Cancer Care Ontario , Toronto, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mina","family":"Tadrous","sequence":"additional","affiliation":[{"name":"Women\u2019s College Hospital , Toronto, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Craig C","family":"Earle","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Medical Oncology, Sunnybrook Health Sciences Centre, University of Toronto , Toronto, ON, Canada"},{"name":"Temerty Faculty of Medicine, University of Toronto , Toronto, ON, Canada"},{"name":"Canadian Partnership Against Cancer , Toronto, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jim J","family":"Biagi","sequence":"additional","affiliation":[{"name":"Department of Oncology, Queen\u2019s University , Kingston, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Mittmann","sequence":"additional","affiliation":[{"name":"Canadian Agency for Drugs and Technologies in Health , Toronto, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Arias","sequence":"additional","affiliation":[{"name":"Ontario Health, Cancer Care Ontario , Toronto, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott","family":"Gavura","sequence":"additional","affiliation":[{"name":"Ontario Health, Cancer Care Ontario , Toronto, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2501-3057","authenticated-orcid":false,"given":"Kelvin K W","family":"Chan","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Medical Oncology, Sunnybrook Health Sciences Centre, University of Toronto , Toronto, ON, Canada"},{"name":"Temerty Faculty of Medicine, University of Toronto , Toronto, ON, Canada"},{"name":"Canadian Centre for Applied Research in Cancer Control , Toronto, ON, Canada"},{"name":"Ontario Health, Cancer Care Ontario , Toronto, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,6,27]]},"reference":[{"key":"2022080310300806700_pkac047-B1"},{"issue":"9","key":"2022080310300806700_pkac047-B2","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1093\/jnci\/djn103","article-title":"Cost of care for elderly cancer patients in the United States","volume":"100","author":"Yabroff","year":"2008","journal-title":"J Natl Cancer Inst"},{"issue":"1","key":"2022080310300806700_pkac047-B3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12885-016-2835-7","article-title":"Phase-specific and lifetime costs of cancer care in Ontario, Canada","volume":"16","author":"de Oliveira","year":"2016","journal-title":"BMC Cancer"},{"issue":"1","key":"2022080310300806700_pkac047-B4","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21332","article-title":"Cancer statistics, 2016","volume":"66","author":"Siegel","year":"2016","journal-title":"CA Cancer J Clin"},{"issue":"18","key":"2022080310300806700_pkac047-B5","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1056\/NEJMoa1304369","article-title":"Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine","volume":"369","author":"Von Hoff","year":"2013","journal-title":"N Engl J Med"},{"issue":"2","key":"2022080310300806700_pkac047-B6","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/dju413","article-title":"nab-Paclitaxel plus gemcitabine for metastatic pancreatic cancer: long-term survival from a phase III trial","volume":"107","author":"Goldstein","year":"2015","journal-title":"J Natl Cancer Inst"},{"issue":"19","key":"2022080310300806700_pkac047-B7","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1056\/NEJMoa1011923","article-title":"FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer","volume":"364","author":"Conroy","year":"2011","journal-title":"N Engl J Med"},{"key":"2022080310300806700_pkac047-B8","year":"2018"},{"key":"2022080310300806700_pkac047-B9","author":"Canadian Agency for Drugs and Technologies in Health","year":"2014"},{"key":"2022080310300806700_pkac047-B10","author":"National Institute for Health and Care Excellence","year":"2017"},{"issue":"1","key":"2022080310300806700_pkac047-B11","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1002\/cam4.2705","article-title":"Real-world outcomes of FOLFIRINOX vs gemcitabine and nab-paclitaxel in advanced pancreatic cancer: a population-based propensity score-weighted analysis","volume":"9","author":"Chan","year":"2020","journal-title":"Cancer Med"},{"issue":"1","key":"2022080310300806700_pkac047-B12","first-page":"23814683211021060","article-title":"Real-world cost-effectiveness of bevacizumab with first-line combination chemotherapy in patients with metastatic colorectal cancer: population-based retrospective cohort studies in three Canadian provinces","volume":"6","author":"Pataky","year":"2021","journal-title":"MDM Policy Pract"},{"issue":"1","key":"2022080310300806700_pkac047-B13","doi-asserted-by":"crossref","first-page":"e032884","DOI":"10.1136\/bmjopen-2019-032884","article-title":"Developing a framework to incorporate real-world evidence in cancer drug funding decisions: the Canadian Real-world Evidence for Value of Cancer Drugs (CanREValue) collaboration","volume":"10","author":"Chan","year":"2020","journal-title":"BMJ Open"},{"key":"2022080310300806700_pkac047-B14","author":"Statistics Canada. Postal Code Conversion File (PCCF)"},{"issue":"7","key":"2022080310300806700_pkac047-B15","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1002\/sim.5984","article-title":"The use of propensity score methods with survival or time-to-event outcomes: reporting measures of effect similar to those used in randomized experiments","volume":"33","author":"Austin","year":"2014","journal-title":"Stat Med"},{"issue":"28","key":"2022080310300806700_pkac047-B16","doi-asserted-by":"crossref","first-page":"3661","DOI":"10.1002\/sim.6607","article-title":"Moving towards best practice when using inverse probability of treatment weighting (IPTW) using the propensity score to estimate causal treatment effects in observational studies","volume":"34","author":"Austin","year":"2015","journal-title":"Stat Med"},{"issue":"25","key":"2022080310300806700_pkac047-B17","doi-asserted-by":"crossref","first-page":"3083","DOI":"10.1002\/sim.3697","article-title":"Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples","volume":"28","author":"Austin","year":"2009","journal-title":"Stat Med"},{"issue":"1","key":"2022080310300806700_pkac047-B18","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1214\/09-STS313","article-title":"Matching methods for causal inference: a review and a look forward","volume":"25","author":"Stuart","year":"2010","journal-title":"Stat Sci"},{"key":"2022080310300806700_pkac047-B19","year":"2013"},{"issue":"4","key":"2022080310300806700_pkac047-B20","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1016\/j.jval.2016.11.002","article-title":"Cost-effectiveness analysis of systemic therapies in advanced pancreatic cancer in the Canadian health care system","volume":"20","author":"Coyle","year":"2017","journal-title":"Value Health"},{"issue":"4","key":"2022080310300806700_pkac047-B21","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1080\/14737167.2020.1812386","article-title":"Cost-effectiveness analysis of nab-paclitaxel plus gemcitabine versus FOLFIRINOX in the treatment of metastatic pancreatic cancer in China","volume":"21","author":"Cui","year":"2020","journal-title":"Expert Rev Pharmacoeconom Outcomes Res"},{"issue":"2","key":"2022080310300806700_pkac047-B22","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.jpainsymman.2011.09.001","article-title":"Does health-related quality of life improve for advanced pancreatic cancer patients who respond to gemcitabine? Analysis of a randomized phase III trial of the cancer and leukemia group B (CALGB 80303)","volume":"43","author":"Romanus","year":"2012","journal-title":"J Pain Symptom Manage"},{"issue":"1","key":"2022080310300806700_pkac047-B23","doi-asserted-by":"crossref","first-page":"e41","DOI":"10.3747\/co.21.1327","article-title":"Cost-effectiveness of FOLFIRINOX for first-line treatment of metastatic pancreatic cancer","volume":"21","author":"Attard","year":"2014","journal-title":"Curr Oncol"},{"issue":"2","key":"2022080310300806700_pkac047-B24","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1093\/biomet\/87.2.329","article-title":"Estimating medical costs with censored data","volume":"87","author":"Bang","year":"2000","journal-title":"Biometrika"},{"key":"2022080310300806700_pkac047-B25","year":"2017","edition":"4th ed."},{"key":"2022080310300806700_pkac047-B26","author":"Wodchis"},{"key":"2022080310300806700_pkac047-B27","author":"Canadian Institute for Health Information"},{"key":"2022080310300806700_pkac047-B28","year":"2015","edition":"2nd ed."},{"issue":"2","key":"2022080310300806700_pkac047-B29","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1002\/pst.433","article-title":"Optimal caliper widths for propensity-score matching when estimating differences in means and differences in proportions in observational studies","volume":"10","author":"Austin","year":"2011","journal-title":"Pharm Stat"},{"issue":"10","key":"2022080310300806700_pkac047-B30","doi-asserted-by":"crossref","first-page":"e108749","DOI":"10.1371\/journal.pone.0108749","article-title":"A Bayesian meta-analysis of multiple treatment comparisons of systemic regimens for advanced pancreatic cancer","volume":"9","author":"Chan","year":"2014","journal-title":"PLoS One"},{"issue":"3","key":"2022080310300806700_pkac047-B31","doi-asserted-by":"crossref","first-page":"294","DOI":"10.5301\/tj.5000499","article-title":"Cost-effectiveness analysis of treatments for metastatic pancreatic cancer based on PRODIGE and MPACT trials","volume":"2016","author":"Zhou","year":"2016","journal-title":"Tumori J"},{"issue":"1","key":"2022080310300806700_pkac047-B32","doi-asserted-by":"crossref","first-page":"125","DOI":"10.3892\/mco.2017.1278","article-title":"Comparing the cost-effectiveness of FOLFIRINOX, nab-paclitaxel plus gemcitabine, gemcitabine and S-1 for the treatment of metastatic pancreatic cancer","volume":"7","author":"Kurimoto","year":"2017","journal-title":"Mol Clin Oncol"},{"key":"2022080310300806700_pkac047-B33","doi-asserted-by":"crossref","first-page":"S33","DOI":"10.1016\/j.jval.2021.04.169","article-title":"PCN77 cost-effectiveness analysis of adjuvant FOLFIRINOX vs gemcitabine\/nab-paclitaxel for resected pancreatic cancer in the United States: based on PRODIGE and APACT trial","volume":"24(suppl 1)","author":"Kharat","year":"2021","journal-title":"Value Health"},{"key":"2022080310300806700_pkac047-B34"},{"issue":"10","key":"2022080310300806700_pkac047-B35","doi-asserted-by":"crossref","first-page":"5163","DOI":"10.21873\/anticanres.11086","article-title":"Bioequivalence of branded and generic oxaliplatin: from preclinical assessment to clinical incidence of hypersensitivity reactions","volume":"36","author":"Tampellini","year":"2016","journal-title":"Anticancer Res"},{"issue":"5","key":"2022080310300806700_pkac047-B36","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1111\/j.1524-4733.2007.00186.x","article-title":"Using real-world data for coverage and payment decisions: the ISPOR Real-World Data Task Force report","volume":"10","author":"Garrison","year":"2007","journal-title":"Value Health"},{"issue":"7","key":"2022080310300806700_pkac047-B37","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1016\/j.jval.2017.03.008","article-title":"What is real-world data? A review of definitions based on literature and stakeholder interviews","volume":"20","author":"Makady","year":"2017","journal-title":"Value Health"},{"issue":"2","key":"2022080310300806700_pkac047-B38","doi-asserted-by":"crossref","first-page":"61","DOI":"10.4103\/picr.PICR_36_18","article-title":"Real world evidence (RWE)-are we (RWE) ready?","volume":"9","author":"Suvarna","year":"2018","journal-title":"Perspect Clin Res"},{"key":"2022080310300806700_pkac047-B39","doi-asserted-by":"crossref","first-page":"295","DOI":"10.2147\/JMDH.S160029","article-title":"Real world data: an opportunity to supplement existing evidence for the use of long-established medicines in health care decision making","volume":"11","author":"Katkade","year":"2018","journal-title":"J Multidiscip Healthc"},{"issue":"12","key":"2022080310300806700_pkac047-B40","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.2217\/cer-2018-0066","article-title":"Real-world evidence for coverage decisions: opportunities and challenges","volume":"7","author":"Hampson","year":"2018","journal-title":"J Comp Eff Res"},{"issue":"8","key":"2022080310300806700_pkac047-B41","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1002\/cncr.32697","article-title":"Assessing the efficacy-effectiveness gap for cancer therapies: a comparison of overall survival and toxicity between clinical trial and population-based, real-world data for contemporary parenteral cancer therapeutics","volume":"126","author":"Phillips","year":"2020","journal-title":"Cancer"},{"issue":"1","key":"2022080310300806700_pkac047-B42","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/s10549-020-05614-5","article-title":"Comparison of outcomes in a population-based cohort of metastatic breast cancer patients receiving anti-HER2 therapy with clinical trial outcomes","volume":"181","author":"Gong","year":"2020","journal-title":"Breast Cancer Res Treat"},{"issue":"1","key":"2022080310300806700_pkac047-B43","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12885-020-06798-1","article-title":"Real-world comparative effectiveness of second-line ipilimumab for metastatic melanoma: a population-based cohort study in Ontario, Canada","volume":"20","author":"Dai","year":"2020","journal-title":"BMC Cancer"},{"issue":"4","key":"2022080310300806700_pkac047-B44","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/j.jval.2016.12.003","article-title":"Policies for use of real-world data in health technology assessment (HTA): a comparative study of six HTA agencies","volume":"20","author":"Makady","year":"2017","journal-title":"Value Health"},{"issue":"1","key":"2022080310300806700_pkac047-B45","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1002\/cam4.2704","article-title":"Are population-based patient-reported outcomes associated with overall survival in patients with advanced pancreatic cancer?","volume":"9","author":"Dai","year":"2020","journal-title":"Cancer Med"},{"key":"2022080310300806700_pkac047-B46","year":"2014"}],"container-title":["JNCI Cancer Spectrum"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jncics\/advance-article-pdf\/doi\/10.1093\/jncics\/pkac047\/44264255\/pkac047.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jncics\/article-pdf\/6\/4\/pkac047\/45217141\/pkac047.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jncics\/article-pdf\/6\/4\/pkac047\/45217141\/pkac047.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,3]],"date-time":"2022-08-03T10:30:56Z","timestamp":1659522656000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jncics\/article\/doi\/10.1093\/jncics\/pkac047\/6618534"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,27]]},"references-count":46,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,7,1]]}},"URL":"https:\/\/doi.org\/10.1093\/jncics\/pkac047","relation":{},"ISSN":["2515-5091"],"issn-type":[{"value":"2515-5091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,8,1]]},"published":{"date-parts":[[2022,6,27]]},"article-number":"pkac047"}}